Research programme: anti-PDGFR alpha and beta monoclonal antibodies - Eli Lilly

Drug Profile

Research programme: anti-PDGFR alpha and beta monoclonal antibodies - Eli Lilly

Alternative Names: Anti-PDGFR monoclonal antibodies - Eli Lilly; PDGFRβ MAb - Eli Lilly

Latest Information Update: 27 Mar 2009

Price : $50

At a glance

  • Originator ImClone Systems
  • Developer Eli Lilly
  • Class Monoclonal antibodies
  • Mechanism of Action Platelet derived growth factor alpha receptor antagonists; Platelet-derived growth factor beta receptor antagonists; Platelet-derived growth factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Solid tumours

Most Recent Events

  • 16 May 2007 Data presented at the 98th Annual Meeting of the American Association for Cancer Research (AACR-2007) added to the Cancer pharmacodynamics section
  • 14 Jun 2005 Preclinical development is ongoing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top